w

RECENT

09/17/2018

Q&A with Dr. Corey A. Carter, President and CEO of EpicentRx Inc. developing “smart” oncolytic virus therapies in combining immuno-oncology agents that activate the human immune system against cancer with minimal toxicity for patients

Interview – CEOCFO Magazine September 17, 2018 Issue

08/09/2018

Radioprotectors: Defensive Weapons In The War On Cancer

“RRx-001 use as radioprotector”

Authors: Scott Caroen, Corey Carter, Bryan Oronsky

05/02/2018

EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines

08/19/2015

EpicentRx Announces Publication of Phase 1 Trial Results for the Anti-Cancer Agent, RRx-001, in Lancet Oncology

05/02/2018

First Patient Treated With Next-Generation Immunotherapy at UC Cincinnati